Department of Biochemistry, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt.
Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Hum Exp Toxicol. 2024 Jan-Dec;43:9603271241251451. doi: 10.1177/09603271241251451.
BACKGROUND & AIMS: The liver is a vital organ responsible for numerous metabolic processes, which can be significantly impacted by long non-coding RNAs (lncRNAs) and microRNAs (miRNAs). These ribonucleic acid (RNA) molecules have been shown to play a crucial role in regulating gene expression, and their dysregulation has been implicated in numerous liver disorders. Our study aimed to investigate the diagnostic accuracy of plasmacytoma variant translocation-1 (PVT-1), microRNA-29a/29b (miR-29a/miR-29b), and inflammatory biomarkers [ interleukine-6 (IL-6), tumor necrosis factor-alpha (TNF-α), transforming growth factor-beta (TGF-β), and insulin growth factor-1 (IGF-1)] as diagnostic and prognostic biomarkers for liver cirrhosis. Therefore, understanding the mechanisms by which lncRNAs and miRNAs influence liver metabolism is of paramount importance in developing effective treatments for liver-related diseases.
Serum samples were collected from 164 participants, comprising 114 cirrhotic patients with varying grades (35 grade I, 35 grade II, and 44 grade III) and 50 healthy controls. PVT-1 and miR-29a/miR-29b expression was analyzed by reverse transcription-quantitative polymerase chain reaction (RT-PCR), while the serum levels of inflammatory biomarkers were assessed using enzyme-linked immunosorbent assay (ELISA).
The study participants exhibited notable differences in PVT-1 and miR-29a/miR-29b expression. ROC analysis revealed excellent discriminative power for PVT-1 and miR-29a/miR-29b in distinguishing cirrhotic patients from healthy controls.
This study demonstrates the promising potential of PVT-1 and miR-29a/miR-29b as early diagnostic biomarkers for liver cirrhosis detection, requiring further validation in larger cohorts. Our findings also reinforce the diagnostic value of circulating inflammatory biomarkers (IL-6, TNF-α, TGF-β, and IGF-1) levels for liver cirrhosis screening.
肝脏是一个重要的器官，负责多种代谢过程，这些过程可能会受到长链非编码 RNA（lncRNA）和 microRNA（miRNA）的显著影响。这些核糖核酸（RNA）分子在调节基因表达方面发挥着关键作用，其失调与许多肝脏疾病有关。我们的研究旨在探讨浆细胞瘤变异易位 1（PVT-1）、microRNA-29a/29b（miR-29a/miR-29b）和炎症生物标志物[白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、转化生长因子-β（TGF-β）和胰岛素样生长因子-1（IGF-1）]作为肝硬化诊断和预后生物标志物的诊断准确性。因此，了解 lncRNA 和 miRNA 影响肝脏代谢的机制对于开发针对肝脏相关疾病的有效治疗方法至关重要。
收集了 164 名参与者的血清样本，其中包括 114 名不同分级的肝硬化患者（35 级 I、35 级 II 和 44 级 III）和 50 名健康对照者。通过逆转录定量聚合酶链反应（RT-PCR）分析 PVT-1 和 miR-29a/miR-29b 的表达，使用酶联免疫吸附试验（ELISA）评估炎症生物标志物的血清水平。
研究参与者的 PVT-1 和 miR-29a/miR-29b 表达存在显著差异。ROC 分析显示，PVT-1 和 miR-29a/miR-29b 在区分肝硬化患者和健康对照者方面具有出色的判别能力。
本研究表明 PVT-1 和 miR-29a/miR-29b 作为肝硬化早期诊断生物标志物具有很大的潜力，需要在更大的队列中进一步验证。我们的研究结果还强调了循环炎症生物标志物（IL-6、TNF-α、TGF-β 和 IGF-1）水平对肝硬化筛查的诊断价值。
